CompletedNCT03541044
A Bioequivalence Study of Two Nicotine Lozenges in Fasting Conditions in Healthy Smokers
Medication studyAges 19–55United StatesAddiction
Understand this study
Who was this study for?
Listed age limits: 19 years to 55 years.
- Listed locations
- LincolnSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: June 18, 2018
- Recruitment status
- Completed
- Enrollment listed in the registry
- 46
- Sponsor
- GlaxoSmithKline
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 19 Years to 55 Years
- Official registry ID
- NCT03541044
- Official title
Show the full official title
A Single Dose Bioequivalence Study of a 2 mg Prototype Mini Nicotine Lozenge vs 2 mg Nicotine Mini Lozenge (Nicorette Minis) Healthy Smokers Under Fasting Conditions
Recruitment & locations
CompletedLincoln
Questions about this study
Who is behind this study?
The study sponsor is GlaxoSmithKline.
Did this study involve medication?
Yes. The study involved medication, including Nicotine Prototype Mini lozenge and Nicorette Mini Lozenge.
Who was this study for?
Listed age limits: 19 years to 55 years.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me